Artificial surface-induced inflammation relies on complement factor 5: Proof from a deficient person

Annals of Thoracic Surgery

Volumn 91, Issue 2, 2011, Pages 527-533

  Bergseth, Grethe ^a,b,c,d   Lambris, John D ^a,b,c,d   Mollnes, Tom Eirik ^a,b,c,d   Lappegrd, Knut Tore ^a,b,c,d  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPSTATIN; CYCLOPEPTIDE; CYTOKINE; ELASTASE; GAMMA INTERFERON; INTERLEUKIN 8; LACTOFERRIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; POLYVINYLCHLORIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BLOOD SAMPLING; COMPLEMENT ACTIVATION; GENETIC DISORDER; HUMAN; INCUBATION TIME; INFLAMMATION; PRIORITY JOURNAL;

BIOCOMPATIBLE MATERIALS; CELL DEGRANULATION; CHEMOKINES; COMPLEMENT ACTIVATION; COMPLEMENT C5; CYTOKINES; ENVIRONMENTAL EXPOSURE; FLOW CYTOMETRY; HUMANS; INFLAMMATION; NEUTROPHILS;

EID: 78751676380     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2010.10.084     Document Type: Article

References (21)

1. C.S. Rinder, H.M. Rinder, and B.R. Smith Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation J Clin Invest 96 1995 1564 1572
2. C.S. Rinder, M.J. Smith, and H.M. Rinder Leukocyte effects of C5a-receptor blockade during simulated extracorporeal circulation Ann Thorac Surg 83 2007 146 152
3. K.T. Lappegard, M. Fung, and G. Bergseth Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation Ann Thorac Surg 77 2004 932 941
4. K.T. Lappegard, M. Fung, G. Bergseth, J. Riesenfeld, and T.E. Mollnes Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition Ann Thorac Surg 78 2004 38 44
5. J.C. Fitch, S. Rollins, and L. Matis Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass Circulation 100 1999 2499 2506
6. K.T. Lappegard, G. Bergseth, and J. Riesenfeld The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent J Biomed Mater Res A 87 2008 129 135
7. T.E. Mollnes, O.L. Brekke, and M. Fung Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation Blood 100 2002 1869 1877
8. K.T. Lappegard, D. Christiansen, and A. Pharo Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature Proc Natl Acad Sci USA 106 2009 15861 15866
9. T.E. Mollnes, J. Riesenfeld, and P. Garred A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin Artif Organs 19 1995 909 917
10. M.A. Seelen, A. Roos, and J. Wieslander Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA J Immunol Methods 296 2005 187 198
11. M. Katragadda, P. Magotti, G. Sfyroera, and J.D. Lambris Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin J Med Chem 49 2006 4616 4622
12. A.M. Finch, A.K. Wong, and N.J. Paczkowski Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a J Med Chem 42 1999 1965 1974
13. T.E. Mollnes, T. Lea, and M. Harboe Detection and quantification of the terminal C5b-9 complex of human complement by a sensitive enzyme-linked immunosorbent assay Scand J Immunol 20 1984 157 166
14. E. Delgado-Cervino, G. Fontan, and M. Lopez-Trascasa C5 complement deficiency in a Spanish family Molecular characterization of the double mutation responsible for the defect Mol Immunol 42 2005 105 111
15. A.E. Asberg, and V. Videm Activation of neutrophil granulocytes in an in vitro model of a cardiopulmonary bypass Artif Organs 29 2005 927 936
16. L.H. Edmunds Inflammatory response to cardiopulmonary bypass Ann Thorac Surg 66 Suppl 1998 12 16
17. R. Solberg, T. Scholz, V. Videm, C. Okkenhaug, and A.O. Aasen Heparin coating reduces cell activation and mediator release in an in vitro venovenous bypass model for liver transplantation Transpl Int 11 1998 252 258
18. V. Videm, T.E. Mollnes, and E. Fosse Heparin-coated cardiopulmonary bypass equipment I. Biocompatibility markers and development of complications in a high-risk population J Thorac Cardiovasc Surg 117 1999 794 802
19. K.T. Lappegard, G. Bergseth, J. Riesenfeld, J. Sexton, and T.E. Mollnes Role of granulocytes and monocytes in the polyvinyl chloride-induced synthesis of interleukin 8, monocyte chemoattractant protein 1, and leukotriene B4 J Biomed Mater Res A 74 2005 230 236
20. K.T. Lappegard, J. Riesenfeld, O.L. Brekke, G. Bergseth, J.D. Lambris, and T.E. Mollnes Differential effect of heparin coating and complement inhibition on artificial surface-induced eicosanoid production Ann Thorac Surg 79 2005 917 923
21. B.C. Hellerud, A. Aase, and T.K. Herstad Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies Infect Immun 78 2010 802 809